Sa1054: COVID-19 EXACERBATES EXISTING DIGESTIVE DISORDERS AND TRIGGERS NEW DIGESTIVE SYMPTOMS AND DIAGNOSES: RESULTS FROM AN INTERNATIONAL PATIENT SURVEY

Barrett-Englert, Meghan; Rao, Aditi; Chey, Samuel W.; Sutton, Alyssa; Taylor, Emily; Chey, William D.

doi:10.1016/s0016-5085(22)60681-4

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The electronic search identified a total of 2057 records; after title screening and duplicates removal, 260 articles were screened and finally 20 full‐text articles were assessed for eligibility (Figure 1). Of the 20 records selected, five studies were excluded for reporting FD or IBS without using Rome criteria, 26–30 three for reporting FD or IBS rates without reporting COVID‐19 diagnosis, 31–33 one for reporting FD and IBS in children 34 and one for inability to extract number of subjects and/or number of events from cases 35 …”

Section: Resultsmentioning

confidence: 99%

“…Of the 20 records selected, five studies were excluded for reporting FD or IBS without using Rome criteria, [26][27][28][29][30] three for reporting FD or IBS rates without reporting COVID-19 diagnosis, [31][32][33] one for reporting FD and IBS in children 34 and one for inability to extract number of subjects and/or number of events from cases. 35 Thus, a total of 10 studies, [12][13][14][36][37][38][39][40][41][42] all full texts, met the eligibility criteria and were included in the meta-analysis.…”

Section: Study Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Marasco

Maida²,

Cremon

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Introduction The burden of post‐COVID‐19 functional dyspepsia (FD) and irritable bowel syndrome (IBS) remains unclear. The aim of this meta‐analysis was to estimate the rate of post‐COVID‐19 FD and IBS. Methods MEDLINE, Scopus and Embase were searched through 17 December 2022. Studies reporting the incidence of FD and/or IBS in COVID‐19 survivors and controls (without COVID‐19), when available, according to the Rome criteria, were included. Estimated incidence with 95% confidence intervals (CI) was pooled. The odds ratio (OR) with 95% confidence intervals (CI) was pooled; heterogeneity was expressed as I2. Results Ten studies met the inclusion criteria and were included in the analysis. Overall, four studies including 1199 COVID‐19 patients were considered for FD. Post‐COVID‐19 FD was reported by 72 patients (4%, 95% CI: 3%–5% and I2 0%). The pooled OR for FD development (three studies) in post‐COVID‐19 patients compared to controls was 8.07 (95% CI: 0.84–77.87, p = 0.071 and I2 = 67.9%). Overall, 10 studies including 2763 COVID‐19 patients were considered for IBS. Post‐COVID‐19 IBS was reported by 195 patients (12%, 95% CI: 8%–16%, I2 95.6% and Egger's p = 0.002 test). The pooled OR for IBS development (four studies) in COVID‐19 patients compared to controls was 6.27 (95% CI: 0.88–44.76, p = 0.067 and I2 = 81.4%); considering only studies with a prospective COVID‐19 cohort (three studies), the pooled OR was 12.92 (95% CI: 3.58–46.60, p < 0.001 and I2 = 0%). Conclusions COVID‐19 survivors were found to be at risk for IBS development compared to controls. No definitive data are available for FD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Marasco

Maida²,

Cremon

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…En total, el 32% reportó exacerbación de sus síntomas, siendo más frecuente la exacerbación de síntomas intestinales (67%), seguido de síntomas gástricos (34%) y esofágicos (15%) 9 . Por otra parte, en una encuesta del International Foundation for Functional Gastrointestinal Disorders (IFFGID), por Barrett-Englert et al, el 72% de los pacientes con TIIC reportó mayor dificultad para manejar sus síntomas gastrointestinales funcionales después de la COVID-19 10 .…”

unclassified

Trastornos de la interacción intestino-cerebro relacionados con COVID-19 y <i>Helicobacter pylori</i> en SII

Saps¹

2022

NGL

View full text Add to dashboard Cite

The COVID‐19 pandemic as a modifier of DGBI symptom severity: A systematic review and meta‐analysis

Kulin,

Shah,

Fairlie

et al. 2024

Neurogastroenterology Motil

View full text Add to dashboard Cite

BackgroundThis SRMA reviewed and assessed the changes in the severity of disorders of gut‐brain interaction (DGBI) symptoms during the COVID‐19 pandemic, and evaluated factors associated with symptom severity changes.MethodsElectronic databases were searched until February 2024, for articles reporting on changes in symptom severity in DGBI patients during the COVID‐19 pandemic. The proportion of DGBI patients who reported a change in their symptom severity were pooled using a random‐effects model, and subgroup analyses were conducted to assess the effect of socio‐cultural modifiers on symptom severity in DGBI.Key ResultsTwelve studies including 3610 DGBI patients found that 31.4% (95% CI, 15.9–52.5) of DGBI patients experienced symptom deterioration, while 24.3% (95% CI, 10.2–47.5) experienced improvement. Countries with high gross domestic product (GDP) had a 43.5% (95% CI, 16.3–75.2) likelihood of symptom deterioration, compared to 9.2% (95% CI, 1.4–42.2) in lower GDP countries. Similarly, countries with low COVID fatality rates had a 60.1% (95% CI, 19.7–90.3) likelihood of symptom deterioration, compared to 18.3% (95% CI, 7.8–36.9) in higher fatality rate countries. Countries with lenient COVID policies had a 58.4% (95% CI, 14.1–92.3) likelihood of symptom deterioration, compared to 19% (95% CI, 8.2–38.1) in countries with stricter policies. Patients in high vaccine hesitancy countries had a 51.4% (95% CI, 19.5–82.2) likelihood of symptom deterioration, compared to 10.6% (95% CI, 2.7–33.4) in low vaccine hesitancy countries.Conclusions & InferencesThis meta‐analysis reveals that a significantly higher proportion of DGBI patients experienced deterioration of symptoms during the COVID‐19 pandemic. Various sociocultural, economic and environmental factors potentially modify the effects of the COVID‐19 pandemic on DGBI.

show abstract

Sa1054: COVID-19 EXACERBATES EXISTING DIGESTIVE DISORDERS AND TRIGGERS NEW DIGESTIVE SYMPTOMS AND DIAGNOSES: RESULTS FROM AN INTERNATIONAL PATIENT SURVEY

Cited by 3 publications

References 0 publications

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Trastornos de la interacción intestino-cerebro relacionados con COVID-19 y <i>Helicobacter pylori</i> en SII

The COVID‐19 pandemic as a modifier of DGBI symptom severity: A systematic review and meta‐analysis

Contact Info

Product

Resources

About